Equities

SSY Group Ltd

SSY Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.20
  • Today's Change0.02 / 0.48%
  • Shares traded3.34m
  • 1 Year change-4.76%
  • Beta0.5841
Data delayed at least 15 minutes, as of Oct 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

  • Revenue in HKD (TTM)6.47bn
  • Net income in HKD1.37bn
  • Incorporated2004
  • Employees5.80k
  • Location
    SSY Group LtdRooms 4902-03, 49th Floor, Central Plaza18 Harbour RoadWanchai Hong KongHKG
  • Phone+852 26880869
  • Fax+852 27873338
  • Websitehttp://www.ssygroup.com.hk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tong Ren Tang Technologies Co Ltd7.55bn714.29m7.15bn4.01k10.010.91775.000.94680.55770.55775.896.080.50260.98815.221,840,563.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m7.43bn779.0015.031.9512.015.390.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Yichang Hec Changjiang Pharmactcl Co Ltd6.08bn1.81bn7.74bn4.89k4.280.81423.691.272.062.066.9110.810.42722.503.741,316,787.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
Shanghai Fudan-Zhangjiang Bio-Pharm. Co807.84m121.46m7.82bn948.0024.461.13--9.680.11530.11530.75952.500.25041.261.35852,156.303.757.034.669.0591.2592.1714.9717.263.78--0.005239.16-17.502.78-21.28-0.632620.49--
China Shineway Pharmaceutical Group Ltd4.61bn1.21bn8.05bn3.23k6.071.005.801.751.601.606.119.740.44761.285.261,343,072.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
AIM Vaccine Co Ltd1.30bn-1.31bn8.13bn1.56k--2.11--6.25-1.08-1.081.073.180.14620.63251.10800,318.30-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd459.39m-1.16bn8.28bn520.00--1.69--18.02-3.59-3.591.4215.090.07565.233.221,063,409.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Cansino Biologics Inc668.99m-951.24m10.69bn1.49k--1.16--15.97-3.85-3.852.7122.480.06761.280.8385447,782.40-10.15-4.27-13.73-5.6014.38---150.19-27.722.19--0.3028---66.52213.94-63.04--30.60--
Luye Pharma Group Ltd6.93bn845.64m12.30bn5.23k14.550.86087.231.780.22480.22481.843.800.2362.443.021,314,909.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
Shanghai Henlius Biotech Inc6.19bn759.89m12.36bn3.55k16.314.3710.612.001.391.3911.345.210.57641.906.821,702,200.007.07-8.5914.25-14.1473.2371.7712.27-27.370.3297.600.6113--67.82273.51178.53--49.14--
SSY Group Ltd6.47bn1.37bn12.42bn5.80k9.141.726.791.920.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
3SBio Inc9.24bn1.82bn16.31bn5.61k9.111.037.221.760.74730.74733.796.590.35751.526.871,708,233.007.257.4410.269.2985.9482.9120.2721.501.57141.550.1998--13.8411.26-19.133.948.78--
Simcere Pharmaceutical Group Ltd6.96bn-1.21bn16.68bn6.41k--2.21--2.40-0.4626-0.46262.702.980.51982.192.64990,578.20-9.0410.17-11.7115.6077.0278.82-17.4017.501.880.47210.146146.684.497.92-23.22-0.521323.93--
Grand Pharmaceutical Group Ltd10.59bn2.41bn17.82bn10.78k7.291.136.201.680.68850.68853.034.430.44723.624.541,005,064.0010.2510.0914.2114.0159.0061.9722.9222.351.09--0.223226.9410.1212.06-9.5921.415.6924.77
Data as of Oct 10 2024. Currency figures normalised to SSY Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

16.28%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management (Hong Kong) Ltd.as of 28 Jun 2024218.06m7.35%
UBS SDIC Fund Management Co., Ltd.as of 08 Mar 202461.15m2.06%
The Vanguard Group, Inc.as of 04 Jul 202453.23m1.79%
Dimensional Fund Advisors LPas of 04 Jul 202429.65m1.00%
FIL Investment Management (Hong Kong) Ltd.as of 30 Jun 202424.72m0.83%
Norges Bank Investment Managementas of 31 Dec 202322.18m0.75%
Bosera Asset Management Co., Ltd.as of 31 Dec 202321.43m0.72%
GF Fund Management Co., Ltd.as of 31 Dec 202317.85m0.60%
Penghua Fund Management Co., Ltd.as of 31 Dec 202317.84m0.60%
BlackRock Fund Advisorsas of 04 Jul 202417.04m0.57%
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.